The Biomarker Partnering Terms and Agreements report provides
comprehensive understanding and unprecedented access to the biomarker
partnering deals and agreements entered into by the worlds leading
healthcare companies.
The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1000 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in biomarker partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.
Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.
Biomarker Partnering Terms and Agreements includes:
The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 550 biomarker deals. Analyzing actual contract agreements allows assessment of the following:
Biomarker Partnering Terms and Agreements provides the reader with the following key benefits:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in biomarker dealmaking
2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Bigpharma biomarker dealmaking activity
2.4. Bigpharma not active in biomarkers
2.5. Biomarker partnering by deal type
2.6. Biomarker partnering by disease type
2.7 Average deal terms for biomarkers
2.7.1 Biomarker headline values
2.7.2 Biomarker upfront payments
2.7.3 Biomarker milestone payments
2.7.4 Biomarker royalty rates
Chapter 3 – Leading biomarker deals
3.1. Introduction
3.2. Top biomarker deals by value
3.3. Top biomarker deals involving bigpharma
Chapter 4 – Bigpharma biomarker deals
4.1. Introduction
4.2. How to use bigpharma biomarker partnering deals
4.3. Bigpharma biomarker partnering company profiles
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Apotex
Astellas
AstraZeneca
Baxter International
Bayer
Bayer Healthcare
Bayer Schering Pharma
Bayer Vital
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genzyme
Genzyme Genetics
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Janssen Pharmaceutica NV
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck Sharpe & Dohme
Merck KGaA
Merck KGaA
Merck Serono
Mitsubishi Tanabe
Mylan
Novartis
Novartis Molecular Diagnostics
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Roche
Roche Applied Science
Roche Diagnostics
Roche Molecular Systems
Roche NimbleGen
Genentech
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Warner Chilcott
Watson
Chapter 5 – Biomarker dealmaking directory
5.1. Introduction
5.2. Company A-Z
5.3. By stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
5.4. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Manufacturing – OEM
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
5.5. By therapy area
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hematology
Hospital care
Immunology
Infectives
Inflammatory
Metabolic
Musculoskeletal
Oncology
Respiratory
Chapter 6 – Biomarker partnering resource center
6.1. Online biomarker partnering
6.2. Biomarker partnering events
6.3. Further reading on biomarker dealmaking
Appendices
Appendix 1 – Deal type definitions
Appendix 2 – Example biomarker partnering agreement
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Table of Figures
Figure 1: Biomarker partnering since 2007
Figure 2: Bigpharma – top 50 – biomarker deals 2007 to 2011
Figure 3: Bigpharma diagnostic deal frequency – 2007 to 2011
Figure 4: Inactive bigpharma in biomarkers 2007-2011
Figure 5: Biomarker partnering by deal type since 2007
Figure 6: Biomarker partnering by disease type since 2007
Figure 7: Biomarker partnering by oncology target since 2007
Figure 8: Biomarker deals with a headline value
Figure 9: Biomarker deal headline value distribution, US$million – 2007-2011 – Discovery stage
Figure 10: Biomarker deal headline value distribution, US$million – 2007-2011 – Discovery stage – detail
Figure 11: Biomarker deals with upfront payment values
Figure 12: Biomarker deals with milestone payments
Figure 13: Biomarker deals with royalty rates, %
Figure 14: Top biomarker deals by value since 2007
Figure 15: Top biomarker deals signed by bigpharma value since 2007
Figure 16: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Cardiovascular)
Figure 17: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Central Nervous System)
Figure 18: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Dental)
Figure 19: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Dermatology)
Figure 20: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Gastrointestinal)
Figure 21: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Genetic disorders)
Figure 22: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Genitourinary)
Figure 23: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Hematology)
Figure 24: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Hospital care)
Figure 25: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Immunology)
Figure 26: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Infectives)
Figure 27: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Inflammatory)
Figure 28: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Metabolic)
Figure 29: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Musculoskeletal)
Figure 30: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Oncology)
Figure 31: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Respiratory)
Figure 32: Online partnering resources
Figure 33: Forthcoming partnering events
Figure 34: Deal type definitions
Figure 35: Biomarker partnering agreement between GlaxoSmithKline and Response Genetics, May 2010
- Trends in biomarker partnering deals
- Biomarker partnering agreement structure
- Biomarker partnering contract documents
- Top biomarker deals by value
- Most active biomarker dealmakers
Biomarker Partnering Terms and Agreements
DiscriptionThe Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1000 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in biomarker partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.
Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.
Biomarker Partnering Terms and Agreements includes:
- Trends in biomarker dealmaking in the biopharma industry since 2075
- Analysis of biomarker deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life biomarker deals
- Access to over 1000 biomarker contract documents
- The leading biomarker deals by value since 2007
- Most active biomarker dealmakers since 2007
- The leading biomarker partnering resources
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 550 biomarker deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise biomarker rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Biomarker Partnering Terms and Agreements provides the reader with the following key benefits:
- In-depth understanding of biomarker deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of biomarker agreements with numerous real life case studies
- Comprehensive access to over 550 actual biomarker contracts entered into by the world’s biopharma companies
- Detailed access to actual biomarker contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a biomarker agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in biomarker dealmaking
2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Bigpharma biomarker dealmaking activity
2.4. Bigpharma not active in biomarkers
2.5. Biomarker partnering by deal type
2.6. Biomarker partnering by disease type
2.7 Average deal terms for biomarkers
2.7.1 Biomarker headline values
2.7.2 Biomarker upfront payments
2.7.3 Biomarker milestone payments
2.7.4 Biomarker royalty rates
Chapter 3 – Leading biomarker deals
3.1. Introduction
3.2. Top biomarker deals by value
3.3. Top biomarker deals involving bigpharma
Chapter 4 – Bigpharma biomarker deals
4.1. Introduction
4.2. How to use bigpharma biomarker partnering deals
4.3. Bigpharma biomarker partnering company profiles
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Apotex
Astellas
AstraZeneca
Baxter International
Bayer
Bayer Healthcare
Bayer Schering Pharma
Bayer Vital
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genzyme
Genzyme Genetics
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Janssen Pharmaceutica NV
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck Sharpe & Dohme
Merck KGaA
Merck KGaA
Merck Serono
Mitsubishi Tanabe
Mylan
Novartis
Novartis Molecular Diagnostics
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Roche
Roche Applied Science
Roche Diagnostics
Roche Molecular Systems
Roche NimbleGen
Genentech
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Warner Chilcott
Watson
Chapter 5 – Biomarker dealmaking directory
5.1. Introduction
5.2. Company A-Z
5.3. By stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
5.4. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Manufacturing – OEM
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
5.5. By therapy area
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hematology
Hospital care
Immunology
Infectives
Inflammatory
Metabolic
Musculoskeletal
Oncology
Respiratory
Chapter 6 – Biomarker partnering resource center
6.1. Online biomarker partnering
6.2. Biomarker partnering events
6.3. Further reading on biomarker dealmaking
Appendices
Appendix 1 – Deal type definitions
Appendix 2 – Example biomarker partnering agreement
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Table of Figures
Figure 1: Biomarker partnering since 2007
Figure 2: Bigpharma – top 50 – biomarker deals 2007 to 2011
Figure 3: Bigpharma diagnostic deal frequency – 2007 to 2011
Figure 4: Inactive bigpharma in biomarkers 2007-2011
Figure 5: Biomarker partnering by deal type since 2007
Figure 6: Biomarker partnering by disease type since 2007
Figure 7: Biomarker partnering by oncology target since 2007
Figure 8: Biomarker deals with a headline value
Figure 9: Biomarker deal headline value distribution, US$million – 2007-2011 – Discovery stage
Figure 10: Biomarker deal headline value distribution, US$million – 2007-2011 – Discovery stage – detail
Figure 11: Biomarker deals with upfront payment values
Figure 12: Biomarker deals with milestone payments
Figure 13: Biomarker deals with royalty rates, %
Figure 14: Top biomarker deals by value since 2007
Figure 15: Top biomarker deals signed by bigpharma value since 2007
Figure 16: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Cardiovascular)
Figure 17: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Central Nervous System)
Figure 18: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Dental)
Figure 19: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Dermatology)
Figure 20: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Gastrointestinal)
Figure 21: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Genetic disorders)
Figure 22: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Genitourinary)
Figure 23: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Hematology)
Figure 24: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Hospital care)
Figure 25: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Immunology)
Figure 26: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Infectives)
Figure 27: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Inflammatory)
Figure 28: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Metabolic)
Figure 29: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Musculoskeletal)
Figure 30: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Oncology)
Figure 31: Recent deals (Jan 2007 to Dec 2011) – By therapy area (Respiratory)
Figure 32: Online partnering resources
Figure 33: Forthcoming partnering events
Figure 34: Deal type definitions
Figure 35: Biomarker partnering agreement between GlaxoSmithKline and Response Genetics, May 2010
